Please login to the form below
biologics
This page shows the latest biologics news and features for those working in and with pharma, biotech and healthcare.
Sinovac begins late-stage COVID-19 vaccine trial
Another Chinese biotech company, CanSino Biologics, also recently announced the launch of a phase 3 clinical trial of its COVID-19 vaccine candidate Ad5-nCOV in Saudi Arabia.
Latest news
-
Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track
The FDA’s acceptance of the aducanumab biologics license application with priority review is an important step in the path to potentially having a treatment that meaningfully changes the course of
-
AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
Our efforts to harness AAV-based gene therapy to produce antibodies directly in the brain and overcome major limitations with delivery of current biologics across the blood-brain barrier have been ... therapeutically efficacious levels of biologics to
-
BMS/bluebird bio resubmit FDA application for myeloma CAR-T
Novel CAR-T therapy targets heavily pre-treated myeloma. Bristol-Myers Squibb and bluebird bio have announced the resubmission of a new biologics license application (BLA) to the US Food and
-
China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
Candidate induced neutralising antibody responses. China-based vaccine specialist CanSino Biologics revealed that its COVID-19 vaccine has shown promise in a phase 2 study.
-
Biogen completes filing for highly-anticipated Alzheimer’s drug
Now that Biogen has completed the Biologics License Application (BLA) and submitted it to the FDA, the regulatory agency has up to 60 days to decide whether to accept it for
More from news
Approximately 20 fully matching, plus 583 partially matching documents found.
Latest Intelligence
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
in the manufacturing of complex biologic therapies, Amgen is leveraging this expertise to meet this growing need.
-
GSK forges ahead with its dynamic COPD and asthma portfolio
You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
-
Developing a COVID-19 vaccine
The volunteers will be isolated for 14 days after being dosed with the adenovirus-based Ad5-nCoV shot, which was developed in collaboration with CanSino Biologics, and will then be monitored
-
Can protein degraders unlock ‘undruggable’ drug targets?
Drug discovery is almost entirely focused on controlling protein activity to treat or cure diseases, using small-molecule or biologics to inhibit or in some cases boost the activity of a
-
Will biosimilars ever catch on in the US?
A decade ago, policymakers tried to use generics as an exemplar for fostering competition in the biologics market. ... The Biologic Price Competition and Innovation (BPCI) Act sought to turn biosimilars into the ‘generics’ of costly biologics.
More from intelligence
Approximately 5 fully matching, plus 83 partially matching documents found.
Latest appointments
-
Ex-BMS exec jumps to Gilead to lead research group
That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.
-
New hires at Crescendo, Healx and Galecto
The latest movers in pharma. Crescendo. Crescendo Biologics has appointed Kenji Hashimoto as its new chief medical officer, who joins Crescendo with over 15 years of experience in oncology and ... Kenji has considerable immuno-oncology expertise and an
-
New hires at FibroGen, Saniona and Turbine
Tuna currently serves as chief scientific officer at Adaptate Biotherapeutics, and has over 15 years of experience in biologics drug discovery and development.
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Bahija has more than 25 years of international leadership experience within the pharmaceutical industry, and joins Immunocore from AstraZeneca, where she has served as President of MedImmune, its global biologics research ... A champion for science and
-
BMS appoints new commercial leader, Davies joins Eisai and more
Commenting on her appointment, Schuermans said: “Sobi has unique capabilities, a heritage in biologics manufacturing, development and supply, and a very exciting future within the rare disease space.
More from appointments
Approximately 8 fully matching, plus 48 partially matching documents found.
Latest from PMHub
-
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen. ... Biobetters are enhanced versions of originator biologics, which potentially offer added value to
-
Innovative pricing and contracting options
3. For new entrants in the biologics space, adopting net pricing options is crucial since some US payers are volume sensitive and may prefer an older competitor drug that is clinically
-
MIT reveals new pill to deliver insulin
Alex:This device enables the delivery of all biologic drugs, not just insulin. ... For example, I confirmed the insulin was still active when pressed into the device and ensured the properties didn’t change considering that we are submitting the
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study.
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
It is easy to perform and is more rapid than traditional chemical or biologic cell transfection techniques. ... does not negatively alter the biologic structure or function of the target cells.
More from PMHub
Approximately 7 fully matching, plus 39 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- 20 for 2020 – Five pharma companies to watch
- Leadership change within Bedrock Group
- Moderna inks R&D agreements with Vertex and Chiesi
- OPEN Health’s Digital team have won a Bronze Award at the PM Society Digital Awards 2020
- New restrictions announced as UK’s COVID-19 alert level is increased
- Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer
- AZ/Merck's Lynparza improves survival in certain prostate cancers
- The flexible salesforce
- Navigating engagement and remote working during the pandemic
PMHub
Havas Life Medicom
We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...
Latest intelligence
- Improve clinical trials through patient journey mapping
- Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
Quick links
Infographics
